After Zepto in Mumbai, Blinkit in Pune faces action; FDA orders closure of dark store at Baner-Balewadi
The Maharashtra Food and Drug Administration (FDA) last week ordered the closure of a dark store associated with quick grocery delivery service Blinkit in Pune's Baner-Balewadi area for allegedly operating without a licence.
Suresh Annapure, Joint Commissioner, FDA, Pune, told The Indian Express that the action was taken on June 5 when an inspection team found improper storage conditions at the facility run by Energy Darkstore Services, one of Blinkit's last-mile warehousing and partners.
'We have asked for proper documents to be submitted to issue a license. There are non-compliance issues, and without permission, they have been operating the store in the Baner-Balewadi area,' Annapure said.
Sources said several issues were identified, including poor cleanliness and improper cold storage.
Food Safety Officer Laxmikant Sawale said the action was taken after the raid revealed a lack of compliance with Schedule 4 of the Food Safety and Standards Act, 2006, which details the general hygienic and sanitary practices that food business operators must adhere to.
'We have directed them to submit a compliance report and then there will be a re-inspection,' Annapure said.
The FDA's action is part of its ongoing crackdown on unsafe food storage practices across the state. Earlier this month, it suspended the food business licence of quick-commerce firm Zepto's parent company Kiranakart Technologies due to lapses found at at its dark store in Mumbai's Dharavi.
The inspection was conducted by Food Safety Officer Ram Bodke, following instructions from Minister of State for FDA Yogesh Kadam and under the supervision of Mangesh Mane, Joint Commissioner of Food. The investigation revealed numerous violations of the Food Safety and Standards Act, 2006, as well as the related licensing regulations, according to the FDA.
Visible fungal growth on food items, stagnant and clogged water near storage areas, which indicated poor sanitation, improper cold storage with temperatures not maintained as per norms, and wet, unclean floors and food products stored haphazardly, including directly on the ground, were some of the findings of the regulator.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
4 hours ago
- Time of India
Major chocolate recall sweeps U.S stores — here's why your favorite sweet treat might be unsafe
Weaver Nut Company is recalling certain semi-sweet chocolate nonpareils distributed throughout the United States. If you recently purchased semi-sweet chocolate nonpareils from a grocery or retail store, you should double-check the lot number. Major chocolate recall sweeps U.S. stores: The U.S. Food and Drug Administration (FDA) announced in a news release on Wednesday that Weaver Nut Company was recalling its semi-sweet chocolate nonpareils with white or Christmas-colored seeds, with particular lot codes, due to possible unreported milk allergies, as per a report by Newsweek. Although no illnesses have been reported, people who are allergic to milk face a serious risk. The chocolates were sold through supermarkets and retail stores throughout the United States. ALSO READ: McDonald's boycott June 24: Who's behind it, why it's happening, and how long it will last Why is your favourite sweet treat unsafe? According to the FDA's release, the problem was discovered after a wholesale customer complained about differences in product specifications. Live Events The chocolates were labelled as being free of milk, but later laboratory testing revealed that they did contain milk proteins, it added. It further stated that consuming the affected items could result in severe or fatal allergic reactions for people with a milk allergy or severe sensitivity. One of the top nine allergens that the FDA requires to be declared is milk, and improper labelling can be very risky. Why is this recall important? According to the Pennsylvania-based Weaver Nut Company, the recall is a preventative step to protect the public's health. The business is taking all necessary steps to ensure the safety of its products. Which chocolates are affected? Customers are advised to verify product lot codes and return or dispose of any impacted items. Throw away the items or return them to the store for a complete refund. Lot numbers 204206, 204207, 204208, 204209, 204212, 224225 are for Item 47518-Nonpareil, Semi-Sweet Chocolate (Christmas Seeds). Lot numbers 204214-RL, 204214, 204215, 224221, 224222, 224223, 135215, 135216, 135217, 135220, 135221, 145204, 145205-1, 145207-1, and 145210-1 are for Item D2645, Nonpareils, Semi-Sweet Chocolate (White Seeds), as per a report by Newsweek. FAQs What do I do if I have these chocolates? Check the lot number, and if it is recalled, do not eat it. Return it for a refund or dispose of it. Why is the recall so serious? Milk is a major allergen, and consuming it when allergic can result in serious or life-threatening reactions. Economic Times WhatsApp channel )
Time of India
20 hours ago
- Time of India
Dose of hope
Times of India's Edit Page team comprises senior journalists with wide-ranging interests who debate and opine on the news and issues of the day. To really help, new HIV vax has to be made cheap A pill to treat multidrug-resistant HIV, lenacapavir, has been approved by US drug regulator FDA as a preventive vaccine. This is a huge deal – incidence of HIV may have declined since 1990s but even today about 13L people globally are infected by the virus every year. But its price is an obstacle. Sold for $28,218 per year in US, it's prohibitive even for high-income nations. Pharma company Gilead that manufactures lenacapavir has reportedly tied up with over 100 middle- and low-income countries for manufacture of generics pending approvals. But access likely will still be tricky for poorer African countries that bear the HIV burden. Drugs to prevent HIV transmission have been around almost a decade, but a daily dosage regimen makes these unreliable. People forget and there's the stigma/doubt in partners that a daily dose is preventive. Lenacapavir needs to be taken just twice a year. Its long-lasting effect in preventing infection – almost 100% in adults and adolescents – is thus the best bet today. Also because HIV research in US bears the additional burden of Trump administration's slashed funds. An effective vaccine for HIV has been elusive for decades because of its rapid mutations. Several mRNA vaccines, like those developed for Covid and considered the most promising, are in clinical trials. But since Jan, under Trump's health secretary Bob Kennedy Jr, NIH stopped funding hundreds of such HIV vaccine-related research. This is what makes repurposed lenacapavir a lifeline, provided it's made affordable. Facebook Twitter Linkedin Email This piece appeared as an editorial opinion in the print edition of The Times of India.
Hans India
a day ago
- Hans India
ZeroHarm Eyes Rs 150 Crore Milestone by FY 2025 -'26, Accelerates Global Expansion into GCC
ZeroHarm Sciences, India's pioneering clean-label nutraceutical company, is set to accelerate its global footprint with a focused expansion into the GCC markets, including the UAE and the broader Middle East. Following a remarkable 10× revenue growth over the past two years and operating at a healthy ~20% EBITDA margin, the company closed the last fiscal year with 71 crore in gross revenue with an exit ARR of 90 crores. In the current fiscal, ZeroHarm is aiming for ₹150 crore in gross revenue, driven by strong domestic and global momentum and increasing traction in the United States, which now contributes nearly 30% of its overall revenue. At the heart of ZeroHarm's global success is its patented ZeroHarm BioEnhance platform, a pharma-grade nanotechnology that encapsulates plant-based actives at the nanoscale, dramatically enhancing their bioavailability by up to 5×, ensuring faster onset, precise dosing, and residue-free delivery. This breakthrough, backed by granted patents and deep R&D, makes ZeroHarm the first Indian company to bring pharmaceutical nanotech into nutraceuticals at scale. ZeroHarm's US FDA, CE, and ISO-certified formulations are backed by government-led clinical trials, with documented claims for 15 products, setting it apart in a market rife with unverified health claims. Today, the company offers over 70 targeted, condition-specific products spanning diabetes, arthritis, PCOS, liver and kidney health, immunity, and oncology support, with over million units sold across India to date. Backed by a fully owned, nanotech-enabled manufacturing facility, ZeroHarm can produce up to ₹250 crore worth of finished goods annually, making it one of the few Indian nutraceutical brands with true end-to-end production capabilities. To support its international expansion, ZeroHarm has acquired a dedicated manufacturing and R&D facility in the United States, enhancing local supply chain efficiency, fast-tracking formulation innovation, and enabling closer clinical and regulatory collaborations in key global markets. The U.S. infrastructure also gives ZeroHarm a significant strategic edge in developed markets, where stringent compliance standards often limit entry for Indian nutraceutical brands reliant on contract manufacturing. 'The global nutraceutical market is shifting, consumers are demanding not just clean labels, but clinical credibility. At ZeroHarm, we've combined deep R&D with pharma-grade nanotechnology to raise the bar for efficacy, safety, and transparency in preventive wellness. Our entry into the GCC is a natural extension of the trust we've built in India and the U.S., and a significant step toward making evidence-backed, plant-based therapeutics accessible to global consumers,' said Sachin Darbarwar, Founder & CEO, ZeroHarm Sciences. With distribution agreements and regulatory filings already underway, the company will also launch in the UK aside from the GCC markets by Q3 2025, introducing its clinically tested product lines via pharmacies, e-commerce platforms, and integrative practitioner networks.
